Breast Cancer Metabolomics Using NMR

  • Uma Sharma
  • Naranamangalam R. Jagannathan
Part of the Methods in Molecular Biology book series (MIMB, volume 2037)


Continued progress is being made in understanding the breast cancer metabolism using analytical magnetic resonance (MR)-based methods like nuclear magnetic resonance (NMR) and in-vivo MR spectroscopy (MRS). Analyses using these methods have enhanced the knowledge of altered biochemical pathways associated with breast cancer progression, regression, and pathogenesis. Comprehensive metabolic profiling of biological samples like tissues, cell lines, fine needle aspirate, and biofluids such as sera and urine enables identification of new biomarkers and abnormalities in biochemical pathways. These methods are not only useful for diagnosis, therapy monitoring, disease progression, and staging of cancer but also for the identification of new therapeutic targets and designing new treatment strategies. Additionally, in-vivo MRS studies have established choline-containing compounds (tCho) as biomarkers of malignancy, which is useful for enhancing the diagnostic specificity of magnetic resonance imaging (MRI). Recent technological developments related to in-vivo MRS such as increased magnetic field strength, multichannel phased array breast coils, and absolute quantification of tCho have provided a better understanding of the tumor heterogeneity, metabolism, and pathogenesis. This chapter focuses on providing the experimental aspects of in-vitro, ex-vivo, and in-vivo MR spectroscopy methods used for metabolomics studies of breast cancer.

Key words

In-vitro NMR Ex-vivo NMR In-vivo MRS Metabolomics Breast cancer Choline Perchloric acid extraction Acetonitrile extraction Chloroform-methanol extraction 



The Science and Engineering Research Board (SERB), Government of India is acknowledged for financial support (SP/S0/B27/95; SP/S0/B21/2001; SP/SO/HS-80/2006 and SR/SO/HS/213/2012) and a J.C. Bose Fellowship to NRJ.


  1. 1.
    Jagannathan NR, Sharma U (2017) Breast tissue metabolism by magnetic resonance spectroscopy. Meta 7:25Google Scholar
  2. 2.
    Bezabeh T, Ijare OB, Nikulin AE et al (2014) MRS-based metabolomics in cancer research. Magn Reson Insights 7:1–14PubMedPubMedCentralGoogle Scholar
  3. 3.
    Tenori L, Oakman C, Morris PG et al (2015) Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study. Mol Oncol 9:128–139CrossRefGoogle Scholar
  4. 4.
    GD T, Miller JA, Chow HH et al (2014) Metabolomic characterization of nipple aspirate fluid by (1) H NMR spectroscopy and GC-MS. J Proteome Res 13:883–889CrossRefGoogle Scholar
  5. 5.
    Nagana Gowda GA, Barding GA Jr, Dai J et al (2018) A metabolomics study of BPTES altered metabolism in human breast cancer cell lines. Front Mol Biosci 5:49CrossRefGoogle Scholar
  6. 6.
    Giskeødegård GF, Grinde MT, Sitter B et al (2010) Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res 9:972–979CrossRefGoogle Scholar
  7. 7.
    Choi JS, Baek HM, Kim S et al (2013) Magnetic resonance metabolic profiling of breast cancer tissue obtained with core needle biopsy for predicting pathologic response to neoadjuvant chemotherapy. PLoS One 8:e83866CrossRefGoogle Scholar
  8. 8.
    Maria RM, Altei WF, Selistre-de-Araujo HS et al (2017) Impact of chemotherapy on metabolic reprogramming: characterization of the metabolic profile of breast cancer MDA-MB-231 cells using 1H HR-MAS NMR spectroscopy. J Pharm Biomed Anal 146:324–328CrossRefGoogle Scholar
  9. 9.
    Fuss TL, Cheng LL (2016) Evaluation of cancer metabolomics using ex vivo high resolution magic angle spinning (HRMAS) magnetic resonance spectroscopy (MRS). Meta 6:11Google Scholar
  10. 10.
    Roebuck JR, Cecil KM, Schnall MD et al (1998) Human breast lesions: characterization with proton MR spectroscopy. Radiology 209:269–275CrossRefGoogle Scholar
  11. 11.
    Jagannathan NR, Kumar M, Seenu V et al (2001) Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016–1022CrossRefGoogle Scholar
  12. 12.
    Sah RG, Sharma U, Parshad R et al (2012) Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study. Magn Reson Med 68:1039–1047CrossRefGoogle Scholar
  13. 13.
    Bolan PJ (2013) Magnetic resonance spectroscopy of the breast: current status. Magn Reson Imaging Clin N Am 21:625–639CrossRefGoogle Scholar
  14. 14.
    Bolan PJ, Meisamy S, Baker EH et al (2003) In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 50:1134–1143CrossRefGoogle Scholar
  15. 15.
    Baik HM, Su MY, Yu HJ et al (2006) Quantification of choline containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 19:96–104CrossRefGoogle Scholar
  16. 16.
    Bakken IJ, Gribbestad IS, Singstad TE et al (2001) External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 tesla. Magn Reson Med 46:189–192CrossRefGoogle Scholar
  17. 17.
    Danishad KK, Sharma U, Sah RG et al (2010) Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 23:233–241PubMedGoogle Scholar
  18. 18.
    Tozaki M, Sakamoto M, Oyama Y et al (2010) Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 31:895–902CrossRefGoogle Scholar
  19. 19.
    Sharma U, Baek HM, Su MY et al (2011) In vivo 1H MRS in the assessment of the therapeutic response of breast cancer patients. NMR Biomed 24:700–711CrossRefGoogle Scholar
  20. 20.
    Beckonert O, Keun HC, Ebbels TM et al (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692–2703CrossRefGoogle Scholar
  21. 21.
    Blekherman G, Laubenbacher R, Cortes DF et al (2011) Bioinformatics tools for cancer metabolomics. Metabolomics 7:329–343CrossRefGoogle Scholar
  22. 22.
    Bolan PJ, DelaBarre L, Baker EH et al (2002) Eliminating spurious lipid sidebands in 1H MRS of breast lesions. Magn Reson Med 48:215–222CrossRefGoogle Scholar
  23. 23.
    Emwas AH, Roy R, McKay RT et al (2016) Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis. J Proteome Res 15:360–73.[PNJ1][PNJ1]

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Uma Sharma
    • 1
  • Naranamangalam R. Jagannathan
    • 1
  1. 1.Department of NMR and MRI FacilityAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations